← SynDRA
CEP-32496
SynDRA canonical compound SYN0029192 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | BRAF |
|---|
| Mechanism of action | RAF inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- RAF inhibitor
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- RAF1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- OPA1
- PEBP1
- PDXK
- PDGFRB
- PASK
- PAK4
- PAK2
- PAICS
- OLA1
- NDUFA13
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- NEK3
- NEK2
- PFKP
- PGRMC1
- PHKG2
- PIK3CA
- PRKAG1
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- PIM2
- PIM1
- PIK3CB
- NEK1
- NAT10
- PRKAR2A
Cross-references
Synonyms
- Agerafenib
- RXDX-105
- AB-024
- AC-013773
- B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
- CEP 32496
- Rxdx 105
- AC013773
- RefChem:110134
- MFCD22124524
- UNII-78I4VEX88N
- C24H22F3N5O5
- CEP32496
- AGERAFENIB [INN]
- AGERAFENIB [WHO-DD]
- CEP-32496 (free base)
- GTPL7880
- orb1306565
- SCHEMBL1015932
- RXDX 105 [WHO-DD]
- SCHEMBL29351427
- SCHEMBL29697285
- DKNUPRMJNUQNHR-UHFFFAOYSA-N
- GLXC-90328
- HMS3653J19
- EX-A1481
- BDBM50382959
- NSC776043
- NSC800070
- s8015
- AKOS023600525
- AKOS032949984
- CCG-269834
- CEP-32496?
- CS-1115
- NSC-776043
- NSC-800070
- SB20796
Look up CEP-32496 in the interactive SynDRA portal →